Oasmia presents in USA
Oasmia's cancer drug one step closer the American market
Between 1-4th of November the clinical results for Oasmia's cancer drug Paclical® Vet will be presented at the annual Veterinary Cancer Society Congress in Florida.
- I am very pleased that our abstract has been accepted for presentation at the Annual Veterinary Cancer Society Congress in Florida. It means that we are going to reach an audience with the best competence in the subject. This will also give us the possibility to discuss and involve the most prominent, says Henrik von Euler, principal veterinarian.
- The congress in USA is a milestone for Oasmia. Our participation is an important step in Oasmia's registration process but most of all for the American veterinary market. In that case Oasmia will be the first company in the world with a registered cytostaticum for dogs, says Julian Aleksov, CEO at Oasmia.
Paclical® Vet has showed surprisingly good results in dogs with cancer where the previous alternative a few years ago was euthanization. Today there are 140 million dogs in EU and USA.
The press release is available in PDF-format here.
